Next Generation Sequencing Market Size, Share, Growth, and Industry Analysis, By Type (Ion semiconductor sequencing,Sequencing by the synthesis (SBS),Nanopore sequencing,Single-molecule real-time (SMRT) sequencing), By Application (Biotechnology and Pharmaceutical Companies,Research Centres,Hospitals & Clinics,Others), Regional Insights and Forecast to 2035

Next Generation Sequencing Market Overview

The global Next Generation Sequencing Market is forecast to expand from USD 24524.94 million in 2026 to USD 29155.25 million in 2027, and is expected to reach USD 116311 million by 2035, growing at a CAGR of 18.88% over the forecast period.

The Next Generation Sequencing (NGS) market has transformed genomic research and clinical diagnostics by offering faster, scalable, and cost-efficient sequencing solutions. In 2024, more than 20 billion DNA bases per day are processed globally using high-throughput sequencing systems, a number that has grown by over 350% since 2015. Sequencing costs have dropped dramatically from USD 100,000 per genome in 2001 to less than USD 600 per genome in 2023, allowing broader adoption across research institutes, hospitals, and pharmaceutical organizations. More than 70% of oncology-related genomic studies worldwide utilize NGS platforms for variant detection, mutation analysis, and precision oncology initiatives.

The United States dominates the Next Generation Sequencing market with more than 45% of the global installations of sequencing platforms concentrated in the country. Over 800 academic research centers, 500 hospitals, and 250 biotech firms in the U.S. actively deploy NGS for clinical diagnostics and research applications. Federal funding programs, such as the National Human Genome Research Institute (NHGRI), have invested more than USD 3 billion cumulatively into sequencing projects since 2010, significantly accelerating innovation.

What is Next Generation Sequencing (NGS)?

Next Generation Sequencing (NGS) is an advanced genomic technology that enables the rapid sequencing of DNA and RNA at a significantly higher speed, accuracy, and throughput than traditional sequencing methods. It is widely used in clinical diagnostics, drug discovery, precision medicine, oncology, infectious disease surveillance, genetic testing, and biomedical research. NGS allows researchers and healthcare professionals to analyze millions of genetic fragments simultaneously, supporting a deeper understanding of diseases and enabling personalized treatment approaches.

Get Comprehensive Insights into the Market’s Size and Growth Trends

Download FREE Sample

Key Findings

• Key Market Driver: 68% of adoption growth is fueled by clinical diagnostics, with oncology accounting for 42% of the share.
• Major Market Restraint: 54% of laboratories cite high infrastructure and operational costs as primary barriers to adoption.
• Emerging Trends: 61% of sequencing applications are shifting toward personalized medicine, while 39% focus on infectious disease surveillance.
• Regional Leadership: North America accounts for 45% of the market, Europe 27%, Asia-Pacific 22%, and the Middle East & Africa 6%.
• Competitive Landscape: Illumina holds 48% market share, Thermo Fisher Scientific 24%, while Oxford Nanopore Technologies accounts for 12%.
• Market Segmentation: Sequencing by synthesis leads with 52% usage, followed by ion semiconductor sequencing at 23%, nanopore at 15%, and SMRT at 10%.
• Recent Development: 43% of innovations since 2022 have focused on portable sequencers, while 37% emphasize data analysis software.

Next Generation Sequencing Market Latest Trends

The Next Generation Sequencing market is witnessing significant technological transformations with the integration of artificial intelligence and cloud-based bioinformatics solutions. More than 70% of laboratories worldwide now leverage AI-powered analysis for variant interpretation, reducing turnaround times by over 60% compared to 2018.

Additionally, the market is experiencing rapid growth in liquid biopsy testing, with more than 1.2 million liquid biopsy samples processed annually using NGS platforms. The integration of NGS into non-invasive prenatal testing (NIPT) has expanded substantially, accounting for over 35% of global prenatal testing volumes in 2023.

Next Generation Sequencing Market Dynamics

DRIVER

"Rising demand for pharmaceuticals."

The increasing demand for pharmaceuticals drives significant adoption of NGS in drug discovery and development. More than 65% of pharmaceutical companies utilize sequencing technologies for biomarker identification, genetic screening, and precision drug design. In 2023, over 1,000 active drug development projects globally incorporated sequencing-based genomic analysis, reflecting its vital role in improving therapeutic outcomes. The rise of biologics and targeted therapies is further strengthening this demand, with sequencing reducing research timelines by 40% compared to traditional methods.

RESTRAINT

"Demand for refurbished equipment."

High costs associated with sequencing instruments remain a barrier, with 54% of small research centers preferring refurbished or second-hand sequencers due to budget limitations. The average upfront cost of high-throughput sequencing systems exceeds USD 1 million, excluding consumables and maintenance expenses. As a result, adoption among small- and mid-scale laboratories remains limited. Furthermore, 41% of labs cite high computational requirements as a challenge, as data analysis can require servers costing over USD 100,000 annually.

OPPORTUNITY

"Growth in personalized medicines."

The growing emphasis on personalized medicine is creating significant opportunities for NGS adoption. More than 60% of precision medicine programs worldwide rely on sequencing platforms for genetic profiling. In oncology, sequencing is applied in over 70% of personalized treatment decisions, while in rare diseases, sequencing enables diagnosis in over 50% of cases previously undiagnosed. Expanding applications in cardiology, neurology, and immunology further highlight the market’s potential. Governments worldwide are investing in personalized medicine initiatives, with over USD 2 billion allocated since 2021 for genome mapping and sequencing programs.

CHALLENGE

"Rising costs and expenditures."

Despite cost reductions, operational expenses remain a challenge. Sequencing consumables account for nearly 65% of the recurring costs per sequencing run, limiting accessibility for smaller institutions. Additionally, data storage presents a significant burden, as a single human genome generates 150 gigabytes of raw data, and large sequencing centers process petabytes annually. More than 38% of laboratories globally identify data management as a bottleneck, citing expenses of USD 30,000 annually for long-term storage solutions.

Why is the Next Generation Sequencing Industry experiencing rapid growth?

The industry is experiencing rapid growth due to increasing adoption of precision medicine, expanding oncology research, growing demand for genetic testing, and advancements in sequencing technologies. NGS has become a critical tool in personalized healthcare, drug development, and disease diagnosis. Clinical diagnostics account for approximately 68% of adoption growth, reflecting the increasing use of sequencing technologies in cancer diagnostics, rare disease detection, prenatal testing, and personalized treatment planning.

Next Generation Sequencing Market Segmentation

The Next Generation Sequencing Market is segmented by type into Ion Semiconductor Sequencing, Sequencing by the Synthesis (SBS), Nanopore Sequencing, and Single-Molecule Real-Time (SMRT) Sequencing, while applications include Biotechnology and Pharmaceutical Companies, Research Centres, Hospitals & Clinics, and Others. Sequencing by the Synthesis (SBS) dominates the market with approximately 63% share due to its high accuracy, scalability, and extensive adoption in genomic research and clinical diagnostics. Nanopore Sequencing accounts for nearly 14%, followed by SMRT Sequencing at 13% and Ion Semiconductor Sequencing at 10%. By application, Biotechnology and Pharmaceutical Companies lead with around 41% share, supported by increasing genomic research, drug discovery activities, and precision medicine initiatives.

Get Comprehensive Insights on the Market Segmentation in this Report

Download FREE Sample

BY TYPE

Ion Semiconductor Sequencing

Ion Semiconductor Sequencing accounts for approximately 10% of the Next Generation Sequencing Market and utilizes semiconductor technology to detect hydrogen ions released during DNA synthesis. Unlike optical-based sequencing methods, this technology directly converts chemical signals into digital information. Modern ion sequencing platforms can generate millions of reads per run and support targeted gene sequencing, oncology studies, and infectious disease detection. The technology is particularly valued for its rapid turnaround times, with certain workflows delivering results within 24 hours. Growing demand for fast and cost-efficient sequencing solutions continues to support adoption among research laboratories and clinical facilities.

Sequencing by the Synthesis (SBS)

Sequencing by the Synthesis (SBS) dominates the market with approximately 63% share and remains the most widely adopted sequencing technology globally. SBS platforms can generate billions of DNA reads in a single sequencing run with accuracy rates exceeding 99%. More than 80% of large-scale genomic projects utilize SBS-based systems due to their reliability and scalability. The technology supports whole-genome sequencing, exome sequencing, transcriptomics, and population genomics research. Continuous improvements in throughput, automation, and data processing capabilities continue to strengthen SBS leadership across academic, clinical, and pharmaceutical applications.

Nanopore Sequencing

Nanopore Sequencing represents approximately 14% of market demand and is recognized for its ability to sequence long DNA fragments in real time. Nanopore devices can generate read lengths exceeding 1 million base pairs, making them highly suitable for structural variant analysis and genome assembly projects. Portable sequencing systems weighing less than 100 grams have enabled field-based genomic analysis in remote environments. Researchers increasingly utilize nanopore technology for pathogen surveillance, environmental monitoring, and precision medicine applications. Ongoing improvements in accuracy and throughput continue to expand commercial adoption.

Single-Molecule Real-Time (SMRT) Sequencing

SMRT Sequencing accounts for approximately 13% of the market and offers long-read sequencing capabilities that support complex genomic studies. The technology enables real-time observation of DNA polymerase activity and can generate read lengths exceeding 20,000 base pairs. SMRT platforms are extensively used in genome assembly, epigenetics, and rare disease research. Long-read sequencing technologies have become increasingly important for resolving genomic regions that are difficult to analyze using short-read methods. Growing demand for comprehensive genomic characterization continues to support segment growth.

By Applications

Biotechnology and Pharmaceutical Companies

Biotechnology and Pharmaceutical Companies account for approximately 41% of the Next Generation Sequencing Market and represent the largest application segment. More than 20,000 biotechnology firms and thousands of pharmaceutical companies globally utilize sequencing technologies for drug discovery, biomarker identification, and clinical development programs. Genomic data supports target validation, patient stratification, and therapeutic development processes. Sequencing technologies are increasingly integrated into precision medicine initiatives and oncology research. Growing investments in genomic-based therapeutics continue to drive demand within this segment.

Research Centres

Research Centres represent approximately 29% of market demand and remain major users of sequencing technologies for genomic, transcriptomic, and epigenetic studies. Thousands of academic institutions and government-funded laboratories worldwide conduct sequencing-based research projects annually. Large-scale genome initiatives often involve sequencing millions of samples to investigate disease mechanisms and population genetics. Increasing availability of high-throughput sequencing platforms continues to expand research capabilities. Public and private funding for genomics research remains a significant driver of adoption.

Hospitals & Clinics

Hospitals & Clinics account for approximately 22% of the market and increasingly utilize sequencing technologies for clinical diagnostics, oncology testing, rare disease detection, and infectious disease surveillance. More than 10,000 hospitals globally have incorporated genomic testing into specialized healthcare services. Sequencing-based diagnostics support personalized treatment planning and improved patient outcomes. Expanding clinical adoption of precision medicine and companion diagnostics continues to strengthen demand. Improvements in workflow automation and turnaround times further support integration into healthcare settings.

Others

The Others segment contributes approximately 8% of market demand and includes forensic laboratories, agricultural genomics facilities, veterinary diagnostics centers, and public health organizations. Sequencing technologies are increasingly applied to food safety testing, biodiversity studies, and environmental monitoring programs. Growing awareness of genomic applications beyond healthcare continues to create opportunities within this segment.

Which segment is expected to witness the fastest growth?

The Sequencing by Synthesis (SBS) segment is expected to maintain its leading position due to its high throughput, accuracy, and broad applicability across clinical and research settings. This segment accounts for approximately 52% of global usage and is extensively utilized for whole-genome sequencing, transcriptomics, exome sequencing, and precision medicine applications.

Next Generation Sequencing Market Regional Outlook

The Next Generation Sequencing Market demonstrates strong global growth supported by increasing genomic research activities, rising adoption of precision medicine, expanding clinical applications, and advancements in sequencing technologies. Government funding programs, biotechnology investments, and healthcare modernization initiatives continue to drive regional market development. Demand is increasing across academic research, pharmaceutical development, and clinical diagnostics sectors.

Get Comprehensive Insights on the Market Segmentation in this Report

Download FREE Sample

NORTH AMERICA

North America dominates the market with approximately 44% share and remains the leading region for genomic research and sequencing technology adoption. The United States hosts more than 6,000 biotechnology companies and hundreds of genomic research institutions utilizing advanced sequencing platforms. Large-scale genomic initiatives have sequenced millions of samples to support disease research and precision medicine programs. More than 50% of global genomic clinical trials are conducted in North America. Strong research funding, advanced healthcare infrastructure, and extensive adoption of genomic diagnostics continue to support regional growth. Sequencing technologies are increasingly integrated into oncology, rare disease diagnosis, and infectious disease monitoring applications.

EUROPE

Europe accounts for approximately 27% of the global Next Generation Sequencing Market and remains a major center for genomic innovation and clinical research. Countries including Germany, the United Kingdom, France, the Netherlands, and Switzerland have established national genomic programs supporting large-scale sequencing initiatives. More than 1 million genomes are expected to be analyzed through various European genomic projects. Academic institutions, healthcare providers, and biotechnology companies continue expanding sequencing capabilities. Precision medicine initiatives and increasing investment in genomic healthcare continue to support market expansion throughout the region.

ASIA-PACIFIC

Asia-Pacific holds approximately 23% of the market and represents one of the fastest-expanding regions for sequencing adoption. China, Japan, South Korea, India, Singapore, and Australia are investing heavily in genomic infrastructure and biotechnology research. The region contains more than 60% of the global population, creating significant opportunities for genomic studies and precision medicine applications. Large national sequencing programs and increasing pharmaceutical research activities continue to drive demand. Expanding healthcare infrastructure and growing awareness of genomic diagnostics support strong regional development.

MIDDLE EAST & AFRICA

Middle East & Africa account for approximately 6% of the global market. Governments and healthcare organizations across the region are increasing investments in genomic medicine, biotechnology research, and precision healthcare initiatives. Countries such as Saudi Arabia, the UAE, Israel, and South Africa are expanding sequencing capabilities through national research programs and healthcare modernization projects. Growing prevalence of genetic disorders and increasing interest in personalized medicine continue to support demand. Improvements in laboratory infrastructure and research capacity are expected to create additional opportunities across the region.

Which region holds the largest market share?

North America holds the largest share of the Next Generation Sequencing industry, accounting for approximately 45% of the global market. The region benefits from advanced healthcare infrastructure, strong genomics research funding, extensive adoption of precision medicine, and a large concentration of sequencing facilities, hospitals, biotechnology companies, and academic research institutions.

List of Top Next Generation Sequencing Companies

• DNAnexus (US)
• Hamilton Company (US)
• BGI Group (China)
• Lucigen (US)
• Thermo Fisher Scientific, Inc. (US)
• GENEWIZ (US)
• Oxford Nanopore Technologies (UK)
• PerkinElmer Inc. (US)
• SciGenom Labs Pvt. Ltd. (India)
• Macrogen (South Korea)
• Takara Bio Inc. (Japan)
• DNASTAR, Inc. (US)
• QIAGEN (Netherlands)
• Becton Dickinson and Company (US)
• Zymo Research (US)
• Partek Incorporated (US)
• Tecan Trading AG (Switzerland)
• Lexogen GmbH (Austria)
• Danaher (US)
• Intrexon Bioinformatics GmbH (Germany)
• Agilent Technologies, Inc. (US)
• Illumina, Inc. (US)

Top Companies with Highest Share:

• Illumina, Inc. holds 48% global market share, dominating sequencing by synthesis platforms.
• Thermo Fisher Scientific, Inc. accounts for 24% share, with strong presence in research and clinical diagnostics.

Investment Analysis and Opportunities

Investments in the Next Generation Sequencing market are accelerating, with more than USD 4 billion in global funding directed toward genomics between 2020 and 2023. Governments in Asia-Pacific have allocated over USD 1.5 billion toward national genome mapping programs.

Opportunities lie in personalized medicine, where 60% of future clinical trials are expected to incorporate sequencing as a core technology. Infectious disease surveillance is another growth area, with over 100 countries integrating NGS into national health strategies.

New Product Development

Innovation in the Next Generation Sequencing market is accelerating, with manufacturers introducing advanced platforms and consumables. In 2023, Illumina launched upgraded sequencing systems capable of generating over 3 terabases of data per run, cutting sequencing time to less than 24 hours.

Thermo Fisher introduced new reagent kits reducing sequencing errors by 30%, improving accuracy for clinical applications. BGI launched automation solutions enabling parallel sequencing of 500 samples per batch, increasing throughput for population-scale studies.

Five Recent Developments

• In 2023, Illumina launched a new sequencing platform capable of 25% higher read accuracy compared to previous models.
• In 2023, Oxford Nanopore introduced an upgraded portable sequencer processing 3 gigabases of data per hour.
• In 2024, Thermo Fisher developed a reagent kit reducing sequencing costs by 20% per sample.
• In 2024, BGI deployed automated sequencing robots processing 1,000 samples simultaneously.
• In 2025, QIAGEN expanded cloud-based bioinformatics software, improving analysis speed by 40%.

Report Coverage of Next Generation Sequencing Market

The Next Generation Sequencing Market Report provides detailed insights into industry performance, growth trends, and technological innovations. Covering over 25 major countries, the report analyzes data from more than 1,500 companies, research centers, and hospitals deploying sequencing technologies.

The report highlights key drivers, restraints, opportunities, and challenges impacting the market. It examines the adoption of sequencing in over 10 clinical applications ranging from oncology and rare diseases to infectious disease surveillance and prenatal testing. Competitive analysis covers 22 major manufacturers with detailed insights into their market share, product portfolios, and strategic initiatives.

Next Generation Sequencing Market Report Coverage

REPORT COVERAGE	DETAILS
Market Size Value In	USD 24524.94 Million in 2026
Market Size Value By	USD 116311 Million by 2035
Growth Rate	CAGR of 18.88% from 2026-2035
Forecast Period	2026 - 2035
Base Year	2025
Historical Data Available	Yes
Regional Scope	Global
Segments Covered	By Type : Ion semiconductor sequencing Sequencing by the synthesis (SBS) Nanopore sequencing Single-molecule real-time (SMRT) sequencing By Application : Biotechnology and Pharmaceutical Companies Research Centres Hospitals & Clinics Others
To Understand the Detailed Market Report Scope & Segmentation Download FREE Sample